1
|
Ter Brugge P, Moser SC, Bièche I, Kristel P, Ibadioune S, Eeckhoutte A, de Bruijn R, van der Burg E, Lutz C, Annunziato S, de Ruiter J, Masliah Planchon J, Vacher S, Courtois L, El-Botty R, Dahmani A, Montaudon E, Morisset L, Sourd L, Huguet L, Derrien H, Nemati F, Chateau-Joubert S, Larcher T, Salomon A, Decaudin D, Reyal F, Coussy F, Popova T, Wesseling J, Stern MH, Jonkers J, Marangoni E. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers. Nat Commun 2023; 14:1958. [PMID: 37029129 PMCID: PMC10082194 DOI: 10.1038/s41467-023-37537-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Accepted: 03/22/2023] [Indexed: 04/09/2023] Open
Abstract
The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer (TNBC), however, the existing methods to identify HRD are controversial and there is a medical need for predictive biomarkers. We assess the in vivo response to platinum agents in 55 patient-derived xenografts (PDX) of TNBC to identify determinants of response. The HRD status, determined from whole genome sequencing, is highly predictive of platinum response. BRCA1 promoter methylation is not associated with response, in part due to residual BRCA1 gene expression and homologous recombination proficiency in different tumours showing mono-allelic methylation. Finally, in 2 cisplatin sensitive tumours we identify mutations in XRCC3 and ORC1 genes that are functionally validated in vitro. In conclusion, our results demonstrate that the genomic HRD is predictive of platinum response in a large cohort of TNBC PDX and identify alterations in XRCC3 and ORC1 genes driving cisplatin response.
Collapse
Affiliation(s)
- Petra Ter Brugge
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Sarah C Moser
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Ivan Bièche
- Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Petra Kristel
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Sabrina Ibadioune
- Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Alexandre Eeckhoutte
- INSERM U830, Institut Curie, PSL University, 75005, Paris, France
- Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Roebi de Bruijn
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Eline van der Burg
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Catrin Lutz
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Stefano Annunziato
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Julian de Ruiter
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | | | - Sophie Vacher
- Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Laura Courtois
- Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Rania El-Botty
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Ahmed Dahmani
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Elodie Montaudon
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Ludivine Morisset
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Laura Sourd
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Léa Huguet
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Heloise Derrien
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Fariba Nemati
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | | | | | - Anne Salomon
- Department of Pathology, Institut Curie, PSL University, 75005, Paris, France
| | - Didier Decaudin
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Fabien Reyal
- Department of Surgery, Institut Curie, PSL University, 75005, Paris, France
| | - Florence Coussy
- Department of Medical Oncology, Institut Curie, PSL University, 75005, Paris, France
| | - Tatiana Popova
- INSERM U830, Institut Curie, PSL University, 75005, Paris, France
- Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Jelle Wesseling
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Marc-Henri Stern
- Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
- INSERM U830, Institut Curie, PSL University, 75005, Paris, France
- Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Jos Jonkers
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands.
| | - Elisabetta Marangoni
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France.
| |
Collapse
|
2
|
Chateau-Joubert S, Hopfe M, Richon S, Decaudin D, Roman-Roman S, Reyes-Gomez E, Bieche I, Nemati F, Dangles-Marie V. Spontaneous mouse lymphoma in patient-derived tumor xenografts: The importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials. Transl Oncol 2021; 14:101133. [PMID: 34051622 PMCID: PMC8170170 DOI: 10.1016/j.tranon.2021.101133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 04/26/2021] [Accepted: 05/19/2021] [Indexed: 11/18/2022] Open
Abstract
Patient-derived tumor xenograft (PDX) is now largely recognized as a key preclinical model for cancer research, mimicking patient tumor phenotype and genotype. Immunodeficient mice, well-known to develop spontaneous lymphoma, are required for PDX growth. As for all animal models used for further clinical translation, a robust experimental design is strongly required to lead to conclusive results. Here we briefly report unintentional co-engraftment of mouse lymphoma during expansion of well-established PDXs to illustrate the importance of systematic check of the PDX identity to avoid misinterpretation. Besides, this quality control based on complementary approaches deserves a more detailed description in materials and methods section to ensure experimental validity and reproducibility.
Collapse
Affiliation(s)
- Sophie Chateau-Joubert
- Unité d'Histologie et d'Anatomie Pathologique, Ecole Nationale Vétérinaire d'Alfort, 94704 Maisons-Alfort, France; Laboratoire d'anatomo-cytopathologie, BioPôle Alfort, Ecole Nationale Vétérinaire d'Alfort, 94704 Maisons-Alfort, France
| | - Miriam Hopfe
- Biologics Testing Solutions, Charles River Biopharmaceutical Services GmbH, Max-Planck-Str. 15A, 40699 Erkrath, Germany
| | - Sophie Richon
- Laboratory of preclinical investigation, Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France; UMR 144, Institut Curie, PSL Research University, CNRS, Paris, France
| | - Didier Decaudin
- Laboratory of preclinical investigation, Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France; Department of Medical Oncology, Institut Curie, 75005 Paris, France
| | - Sergio Roman-Roman
- Laboratory of preclinical investigation, Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France; Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Edouard Reyes-Gomez
- Unité d'Histologie et d'Anatomie Pathologique, Ecole Nationale Vétérinaire d'Alfort, 94704 Maisons-Alfort, France; Laboratoire d'anatomo-cytopathologie, BioPôle Alfort, Ecole Nationale Vétérinaire d'Alfort, 94704 Maisons-Alfort, France; U955 - IMRB, Inserm, Ecole Nationale Vétérinaire d'Alfort, UPEC, Maisons-Alfort F-94700, France
| | - Ivan Bieche
- Department of Genetics, Pharmacogenomics Unit, Institut Curie, PSL Research University, Paris, France; Faculty of Pharmacy, Université Paris Descartes, Paris, France
| | - Fariba Nemati
- Laboratory of preclinical investigation, Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Virginie Dangles-Marie
- Laboratory of preclinical investigation, Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France; Faculty of Pharmacy, Université Paris Descartes, Paris, France; In vivo Experiment Platform, PSL Research University, 75005 Paris, France.
| |
Collapse
|
3
|
Jacquemetton J, Kassem L, Poulard C, Dahmani A, De Plater L, Montaudon E, Sourd L, Morisset L, El Botty R, Chateau-Joubert S, Vacher S, Bièche I, Treilleux I, Trédan O, Marangoni E, Le Romancer M. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant. Breast Cancer Res 2021; 23:57. [PMID: 34020697 PMCID: PMC8139055 DOI: 10.1186/s13058-021-01433-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Accepted: 04/26/2021] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Endocrine therapies targeting estrogen signaling have significantly improved breast cancer (BC) patient survival, although 40% of ERα-positive BCs do not respond to those therapies. Aside from genomic signaling, estrogen triggers non-genomic pathways by forming a complex containing methylERα/Src/PI3K, a hallmark of aggressiveness and resistance to tamoxifen. We aimed to confirm the prognostic value of this complex and investigated whether its targeting could improve tumor response in vivo. METHODS The interaction of ERα/Src and ERα/PI3K was studied by proximity ligation assay (PLA) in a cohort of 440 BC patients. We then treated patient-derived BC xenografts (PDXs) with fulvestrant or the PI3K inhibitor alpelisib (BYL719) alone or in combination. We analyzed their anti-proliferative effects on 6 ERα+ and 3 ERα- PDX models. Genomic and non-genomic estrogen signaling were assessed by measuring ERα/PI3K interaction by PLA and the expression of estrogen target genes by RT-QPCR, respectively. RESULTS We confirmed that ERα/Src and ERα/PI3K interactions were associated with a trend to poorer survival, the latter displaying the most significant effects. In ERα+ tumors, the combination of BYL719 and fulvestrant was more effective than fulvestrant alone in 3 models, irrespective of PI3K, PTEN status, or ERα/PI3K targeting. Remarkably, resistance to fulvestrant was associated with non-genomic ERα signaling, since genomic degradation of ERα was unaltered in these tumors, whereas the treatment did not diminish the level of ERα/PI3K interaction. Interestingly, in 2 ERα- models, fulvestrant alone impacted tumor growth, and this was associated with a decrease in ERα/PI3K interaction. CONCLUSIONS Our results demonstrate that ERα/PI3K may constitute a new prognostic marker, as well as a new target in BC. Indeed, resistance to fulvestrant in ERα+ tumors was associated with a lack of impairment of ERα/PI3K interaction in the cytoplasm. In addition, an efficient targeting of ERα/PI3K in ERα- tumors could constitute a promising therapeutic option.
Collapse
Affiliation(s)
- Julien Jacquemetton
- Université de Lyon, F-69000, Lyon, France.,Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.,CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
| | - Loay Kassem
- Clinical Oncology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Coralie Poulard
- Université de Lyon, F-69000, Lyon, France.,Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.,CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
| | - Ahmed Dahmani
- Translational Research Department, Institut Curie, PSL University, 75005, Paris, France
| | - Ludmilla De Plater
- Translational Research Department, Institut Curie, PSL University, 75005, Paris, France
| | - Elodie Montaudon
- Translational Research Department, Institut Curie, PSL University, 75005, Paris, France
| | - Laura Sourd
- Translational Research Department, Institut Curie, PSL University, 75005, Paris, France
| | - Ludivine Morisset
- Translational Research Department, Institut Curie, PSL University, 75005, Paris, France
| | - Rania El Botty
- Translational Research Department, Institut Curie, PSL University, 75005, Paris, France
| | - Sophie Chateau-Joubert
- École Nationale Vétérinaire d'Alfort, BioPôle Alfort, 94704, Maisons-Alfort Cedex, France
| | | | - Ivan Bièche
- Genetics Department, Institut Curie, Paris, France
| | - Isabelle Treilleux
- Université de Lyon, F-69000, Lyon, France.,Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.,CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.,Pathology Department, Centre Léon Bérard, F-69000, Lyon, France
| | - Olivier Trédan
- Université de Lyon, F-69000, Lyon, France.,Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.,CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.,Medical Oncology Department, Centre Léon Bérard, F-69000, Lyon, France
| | - Elisabetta Marangoni
- Translational Research Department, Institut Curie, PSL University, 75005, Paris, France
| | - Muriel Le Romancer
- Université de Lyon, F-69000, Lyon, France. .,Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France. .,CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France. .,Centre de Recherche en Cancérologie de Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Bâtiment D, 28 rue Laennec, 69373, Lyon Cedex 08, France.
| |
Collapse
|
4
|
Coussy F, El Botty R, Lavigne M, Gu C, Fuhrmann L, Briaux A, de Koning L, Dahmani A, Montaudon E, Morisset L, Huguet L, Sourd L, Painsec P, Chateau-Joubert S, Larcher T, Vacher S, Melaabi S, Salomon AV, Marangoni E, Bieche I. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. J Hematol Oncol 2020; 13:13. [PMID: 32087759 PMCID: PMC7036180 DOI: 10.1186/s13045-020-0846-y] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Accepted: 01/27/2020] [Indexed: 12/14/2022] Open
Abstract
Background Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with alterations to genes of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. The objective of this study was to determine the response to PI3K and MAPK pathway inhibitors in patient-derived xenografts (PDXs) of MBCs with targetable alterations. Methods We compared survival between triple-negative MBCs and other histological subtypes, in a clinical cohort of 323 TNBC patients. PDX models were established from primary breast tumors classified as MBC. PI3K-AKT-mTOR and RTK-MAPK pathway alterations were detected by targeted next-generation sequencing (NGS) and analyses of copy number alterations. Activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways was analyzed with reverse-phase protein arrays (RPPA). PDXs carrying an activating mutation of PIK3CA and genomic changes to the RTK-MAPK signaling pathways were treated with a combination consisting of a PI3K inhibitor and a MEK inhibitor. Results In our clinical cohort, the patients with MBC had a worse prognosis than those with other histological subtypes. We established nine metaplastic TNBC PDXs. Three had a pathogenic mutation of PIK3CA and additional alterations to genes associated with RTK-MAPK signaling. The MBC PDXs expressed typical EMT and stem cell genes and were of the mesenchymal or mesenchymal stem-like TNBC subtypes. On histological analysis, MBC PDXs presented squamous or chondroid differentiation. RPPA analysis showed activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. In vivo, the combination of PI3K and MAPK inhibitors displayed marked antitumor activity in PDXs carrying genomic alterations of PIK3CA, AKT1, BRAF, and FGFR4. Conclusion The treatment of metaplastic breast cancer PDXs by activation of the PI3K-AKT-mTOR and RTK-MAPK pathways at the genomic and protein levels with a combination of PI3K and MEK inhibitors resulted in tumor regression in mutated models and may therefore be of interest for therapeutic purposes.
Collapse
Affiliation(s)
- F Coussy
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France. .,Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France. .,Department of Medical Oncology, Institut Curie, Paris, France.
| | - R El Botty
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - M Lavigne
- Department of Biopathology, Institut Curie, Paris, France
| | - C Gu
- Department of Biopathology, Institut Curie, Paris, France
| | - L Fuhrmann
- Department of Biopathology, Institut Curie, Paris, France
| | - A Briaux
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
| | - L de Koning
- Translational Research Department, RPPA Platform, Institut Curie Research Center, Paris, France
| | - A Dahmani
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - E Montaudon
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - L Morisset
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - L Huguet
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - L Sourd
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - P Painsec
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - S Chateau-Joubert
- BioPôle Alfort, National Veterinary School of Alfort, Maison Alfort, France
| | - T Larcher
- INRA, APEX-PAnTher, Oniris, Nantes, France
| | - S Vacher
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
| | - S Melaabi
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
| | | | - E Marangoni
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - I Bieche
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France.,Inserm U1016, University Paris Descartes, Paris, France
| |
Collapse
|
5
|
Pancholi S, Leal MF, Ribas R, Simigdala N, Schuster E, Chateau-Joubert S, Zabaglo L, Hills M, Dodson A, Gao Q, Johnston SR, Dowsett M, Cosulich SC, Marangoni E, Martin LA. Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. Breast Cancer Res 2020; 22:14. [PMID: 32005287 PMCID: PMC6993431 DOI: 10.1186/s13058-020-1254-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Sunil Pancholi
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | - Mariana Ferreira Leal
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | - Ricardo Ribas
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | - Nikiana Simigdala
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | - Eugene Schuster
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | | | - Lila Zabaglo
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | - Margaret Hills
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, SW3 6JJ, UK
| | - Andrew Dodson
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, SW3 6JJ, UK
| | - Qiong Gao
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | | | - Mitch Dowsett
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, SW3 6JJ, UK
| | | | | | - Lesley-Ann Martin
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK.
| |
Collapse
|
6
|
Coussy F, Lavigne M, de Koning L, Botty RE, Nemati F, Naguez A, Bataillon G, Ouine B, Dahmani A, Montaudon E, Painsec P, Chateau-Joubert S, Laetitia F, Larcher T, Vacher S, Chemlali W, Briaux A, Melaabi S, Salomon AV, Guinebretiere JM, Bieche I, Marangoni E. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics 2020; 10:1531-1543. [PMID: 32042320 PMCID: PMC6993232 DOI: 10.7150/thno.36182] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Accepted: 10/18/2019] [Indexed: 02/07/2023] Open
Abstract
Luminal androgen receptor (LAR) breast cancer accounts for 10% of all triple-negative breast cancers (TNBC). Anti-androgen therapy for this subtype is in development, but yields only partial clinical benefits. In this study, we aimed to characterize the genomic alterations of LAR TNBC, to analyze activation of the PI3K signaling pathway and to compare the response to PI3K pathway inhibitors with that to anti-androgen therapy in patient-derived xenografts (PDX) of LAR TNBC. Methods: Four LAR PDX models were identified, on the basis of their transcriptomic profiles, in a cohort of 57 PDX models of TNBC. The expression of AR-related genes, basal and luminal cytokeratins and EMT genes was analyzed by RT-PCR and IHC. AKT1 and PIK3CA mutations were identified by targeted NGS, and activation of the PI3K pathway was analyzed with a reverse-phase protein array. Three LAR PDXs with a PIK3CA or AKT1 mutation were treated with the AR inhibitor enzalutamide, a PI3K inhibitor, a dual PI3K-mTOR inhibitor and a mTORC1-mTORC2 inhibitor. Finally, we screened a clinical cohort of 329 TNBC for PIK3CA and AKT1 hotspot mutations. Results: LAR TNBC PDXs were significantly enriched in PIK3CA and AKT1 mutations, and had higher levels of luminal-androgen-like gene expression and a higher PI3K pathway protein activation score than other TNBC subtypes. Immunohistochemistry analysis revealed strong expression of the luminal cytokeratin CK18 and AR in three LAR PDX models. We found that mTOR and PI3K inhibitors had marked antitumor activity in vivo in PDX harboring genomic alterations of PIK3CA and AKT1 genes that did not respond to the AR antagonist enzalutamide. PIK3CA mutations were detected in more than one third of AR+ TNBC from patients (38%), and only 10% of AR-negative TNBC. Conclusion: Our results for PDX models of LAR TNBC resistant to enzalutamide indicate that PIK3CA and AKT1 are potential therapeutic targets.
Collapse
|
7
|
Pancholi S, Leal MF, Ribas R, Simigdala N, Schuster E, Chateau-Joubert S, Zabaglo L, Hills M, Dodson A, Gao Q, Johnston SR, Dowsett M, Cosulich SC, Maragoni E, Martin LA. Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. Breast Cancer Res 2019; 21:135. [PMID: 31801615 PMCID: PMC6894349 DOI: 10.1186/s13058-019-1222-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Accepted: 10/30/2019] [Indexed: 01/14/2023] Open
Abstract
Background Endocrine therapies are still the main strategy for the treatment of oestrogen receptor-positive (ER+) breast cancers (BC), but resistance remains problematic. Cross-talk between ER and PI3K/AKT/mTORC has been associated with ligand-independent transcription of ER. We have previously reported the anti-proliferative effects of the combination of everolimus (an mTORC1 inhibitor) with endocrine therapy in resistance models, but potential routes of escape via AKT signalling can lead to resistance; therefore, the use of dual mTORC1/2 inhibitors has met with significant interest. Methods To address this, we tested the effect of vistusertib, a dual mTORC1 and mTORC2 inhibitor, in a panel of endocrine-resistant and endocrine-sensitive ER+ BC cell lines, with varying PTEN, PIK3CA and ESR1 mutation status. End-points included proliferation, cell signalling, cell cycle and effect on ER-mediated transcription. Two patient-derived xenografts (PDX) modelling endocrine resistance were used to assess the efficacy of vistusertib, fulvestrant or the combination on tumour progression, and biomarker studies were conducted using immunohistochemistry and RNA-seq technologies. Results Vistusertib caused a dose-dependent decrease in proliferation of all the cell lines tested and reduced abundance of mTORC1, mTORC2 and cell cycle markers, but caused an increase in abundance of EGFR, IGF1R and ERBB3 in a context-dependent manner. ER-mediated transcription showed minimal effect of vistusertib. Combined therapy of vistusertib with fulvestrant showed synergy in two ER+ PDX models of resistance to endocrine therapy and delayed tumour progression after cessation of therapy. Conclusions These data support the notion that models of acquired endocrine resistance may have a different sensitivity to mTOR inhibitor/endocrine therapy combinations.
Collapse
Affiliation(s)
- Sunil Pancholi
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | - Mariana Ferreira Leal
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | - Ricardo Ribas
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | - Nikiana Simigdala
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | - Eugene Schuster
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | | | - Lila Zabaglo
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | - Margaret Hills
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, SW3 6JJ, UK
| | - Andrew Dodson
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, SW3 6JJ, UK
| | - Qiong Gao
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK
| | | | - Mitch Dowsett
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, SW3 6JJ, UK
| | | | | | - Lesley-Ann Martin
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK.
| |
Collapse
|
8
|
Montaudon E, Nikitorowicz-Buniak J, Sourd L, Botty RE, Dahmani A, Huguet L, Morriset L, Painsec P, Nemati F, Vacher S, Chateau-Joubert S, Pancholi S, Rega C, Ribas R, Nicolas A, Meseure D, Salomon A, Tariq Z, Driouch K, Coussy F, Dutertre G, Cottu P, Bièche I, Martin LA, Marangoni E. Abstract 925: PDX models of ER+ endocrine-resistant metastatic breast cancer identify Polo-like kinase 1 (PLK1) as a therapeutic target. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Metastatic estrogen receptor positive (ER+) breast cancers (BC) are genetically heterogeneous and a significant proportion of patients display intrinsic or acquired resistance to endocrine treatments, mTOR and CDK4/6 inhibitors. The objective of this study was to identify new therapies in clinically relevant PDX models of metastatic ER+ BC progressing on endocrine treatment and/or palbociclib.
Methods: PDX models were generated by engraftment of spinal bone metastases from 120 BC patients. PDXs were molecularly characterized using SNP-arrays, targeted exome sequencing and global gene expression (GEX) analysis. The anti-tumor efficacy of the PLK1 inhibitor volasertib was evaluated in vivo compared to fulvestrant and palbociclib in two PDX models. PLK1 abundance was analyzed by immunohistochemistry in PDXs and compared with the original primary tumor and bone metastasis from each patient. PLK1 expression measured by RT-PCR was assessed in a cohort of 441 BC patients with 15-year follow-up. GEX analysis of PLK1was assessed in patients treated with neoadjuvant anastrazole. Mechanistic studies were performed in a panel of endocrine resistant BC cell lines.
Results: Ten PDX have been established, 8 were ER+ and 2 triple-negative (TN). Genomic alterations included mutations in AKT1, PI3KCA, BRCA2, GATA3, NF1, and amplifications of FGFR1, CCND1 and CCNE2. Comparative pathway analysis of bone metastases derived PDX and patients' primary tumors showed enrichment for pathways associated with mitotic nuclear division, chromatid segregation and G2/M transition. PLK1 was the top commonly up-regulated gene within these pathways. Treatment of an endocrine-resistant ER+ PDX, harboring amplification of CCND1, CCNE2, FGFR1 and high expression of CDK1, showed only partial response to palbociclib and resistance to the FGFR inhibitor, AZD4547. However, PLK1 inhibitor volasertib induced rapid tumor shrinkage and complete response within 5 weeks. Importantly, volasertib was also highly effective when tested as second line therapy in palbociclib pre-treated xenografts. In-vitro inhibition of PLK1 by siRNA or volasertib inhibited tumor proliferation without affecting the expression of ER-regulated genes, suggesting an ER-independent function of PLK1 in regulating cell proliferation. Assessment of the clinical validity of PLK1 expression, revealed a strong association with poor metastases free survival (p<0.0001) in ER+ BC, but not in HER2+ or TNBC. Finally, in a cohort of patients treated with neoadjuvant anastrozole, on-treatment gene expression of PLK1 was significantly (p<0.0001) associated with poor response.
Conclusion: We show that inhibition of PLK1 is a new potential treatment strategy for metastatic ER+ BC. Additional experiments are ongoing in PDX and cell lines to investigate G2/M phase dependence of ER+ BC and to identify predictive biomarkers.
Citation Format: Elodie Montaudon, Joanna Nikitorowicz-Buniak, Laura Sourd, Rania El Botty, Ahmed Dahmani, Léa Huguet, Ludivine Morriset, Pierre Painsec, Fariba Nemati, Sophie Vacher, Sophie Chateau-Joubert, Sunil Pancholi, Camilla Rega, Ricardo Ribas, André Nicolas, Didier Meseure, Anne Salomon, Zakia Tariq, Keltouma Driouch, Florence Coussy, Guillaume Dutertre, Paul Cottu, Ivan Bièche, Lesley-Ann Martin, Elisabetta Marangoni. PDX models of ER+ endocrine-resistant metastatic breast cancer identify Polo-like kinase 1 (PLK1) as a therapeutic target [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 925.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Camilla Rega
- 2Institute of Cancer Research, London, United Kingdom
| | - Ricardo Ribas
- 2Institute of Cancer Research, London, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Coussy F, de Koning L, Lavigne M, Bernard V, Ouine B, Boulai A, El Botty R, Dahmani A, Montaudon E, Assayag F, Morisset L, Huguet L, Sourd L, Painsec P, Callens C, Chateau-Joubert S, Servely JL, Larcher T, Reyes C, Girard E, Pierron G, Laurent C, Vacher S, Baulande S, Melaabi S, Vincent-Salomon A, Gentien D, Dieras V, Bieche I, Marangoni E. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer. Int J Cancer 2019; 145:1902-1912. [PMID: 30859564 DOI: 10.1002/ijc.32266] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Revised: 12/26/2018] [Accepted: 02/19/2019] [Indexed: 12/31/2022]
Abstract
Triple-negative breast cancer (TNBC) represents 10% of all breast cancers and is a very heterogeneous disease. Globally, women with TNBC have a poor prognosis, and the development of effective targeted therapies remains a real challenge. Patient-derived xenografts (PDX) are clinically relevant models that have emerged as important tools for the analysis of drug activity and predictive biomarker discovery. The purpose of this work was to analyze the molecular heterogeneity of a large panel of TNBC PDX (n = 61) in order to test targeted therapies and identify biomarkers of response. At the gene expression level, TNBC PDX represent all of the various TNBC subtypes identified by the Lehmann classification except for immunomodulatory subtype, which is underrepresented in PDX. NGS and copy number data showed a similar diversity of significantly mutated gene and somatic copy number alteration in PDX and the Cancer Genome Atlas TNBC patients. The genes most commonly altered were TP53 and oncogenes and tumor suppressors of the PI3K/AKT/mTOR and MAPK pathways. PDX showed similar morphology and immunohistochemistry markers to those of the original tumors. Efficacy experiments with PI3K and MAPK inhibitor monotherapy or combination therapy showed an antitumor activity in PDX carrying genomic mutations of PIK3CA and NRAS genes. TNBC PDX reproduce the molecular heterogeneity of TNBC patients. This large collection of PDX is a clinically relevant platform for drug testing, biomarker discovery and translational research.
Collapse
Affiliation(s)
- Florence Coussy
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France.,Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France.,Department of Medical Oncology, Institut Curie, Paris, France
| | - Leanne de Koning
- Translational Research Department, RPPA Platform, Institut Curie Research Center, Paris, France
| | - Marion Lavigne
- Department of Biopathology, Institut Curie, Paris, France
| | - Virginie Bernard
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
| | - Berengere Ouine
- Translational Research Department, RPPA Platform, Institut Curie Research Center, Paris, France
| | - Anais Boulai
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
| | - Rania El Botty
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - Ahmed Dahmani
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - Elodie Montaudon
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - Franck Assayag
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - Ludivine Morisset
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - Lea Huguet
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - Laura Sourd
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - Pierre Painsec
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| | - Celine Callens
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
| | | | - Jean-Luc Servely
- BioPôle Alfort, National Veterinary School of Alfort, Maison Alfort, France
| | | | - Cecile Reyes
- Translational Research Department, Genomics Platform, Institut Curie Research Center, Paris, France
| | | | - Gaelle Pierron
- Unit of Somatic Genomics, Department of Genetics, Institut Curie, Paris, France
| | | | - Sophie Vacher
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
| | - Sylvain Baulande
- Genomics of Excellence (ICGex) Platform, Institut Curie Research Center, Paris, France
| | - Samia Melaabi
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
| | | | - David Gentien
- Translational Research Department, Genomics Platform, Institut Curie Research Center, Paris, France
| | | | - Ivan Bieche
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France.,Inserm U1016, Paris Descartes University, Paris, France
| | - Elisabetta Marangoni
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
| |
Collapse
|
10
|
Tury S, Assayag F, Bonin F, Chateau-Joubert S, Servely JL, Vacher S, Becette V, Caly M, Rapinat A, Gentien D, de la Grange P, Schnitzler A, Lallemand F, Marangoni E, Bièche I, Callens C. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers. J Pathol 2018; 246:103-114. [PMID: 29876931 DOI: 10.1002/path.5104] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Revised: 05/01/2018] [Accepted: 05/17/2018] [Indexed: 12/20/2022]
Abstract
To ensure their high proliferation rate, tumor cells have an iron metabolic disorder causing them to have increased iron needs, making them more susceptible to iron deprivation. This vulnerability could be a therapeutic target. In breast cancers, the development of new therapeutic approaches is urgently needed for patients with triple-negative tumors, which frequently relapse after chemotherapy and suffer from a lack of targeted therapies. In this study, we demonstrated that deferasirox (DFX) synergises with standard chemotherapeutic agents such as doxorubicin, cisplatin and carboplatin to inhibit cell proliferation and induce apoptosis and autophagy in triple-negative breast cancer (TNBC) cells. Moreover, the combination of DFX with doxorubicin and cyclophosphamide delayed recurrences in breast cancer patient-derived xenografts without increasing the side-effects of chemotherapies alone or altering the global iron storage of mice. Antitumor synergy of DFX and doxorubicin seems to involve downregulation of the phosphoinositide 3-kinase and nuclear factor-κB pathways. Iron deprivation in combination with chemotherapy could thus help to improve the effectiveness of chemotherapy in TNBC patients without increasing toxicity. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Sandrine Tury
- Pharmacogenomic Unit, Genetics Department, Curie Institute, PSL Research University, Paris, France
| | - Franck Assayag
- Laboratory of Preclinical Investigations, Translational Research Department, Curie Institute, PSL Research University Paris, France
| | - Florian Bonin
- Pharmacogenomic Unit, Genetics Department, Curie Institute, PSL Research University, Paris, France
| | | | - Jean-Luc Servely
- BioPôle Alfort, National Veterinary School of Alfort, Maisons-Alfort, France.,PHASE Department, INRA, Paris, France
| | - Sophie Vacher
- Pharmacogenomic Unit, Genetics Department, Curie Institute, PSL Research University, Paris, France
| | - Véronique Becette
- Department of Biopathology, Curie Institute, René Huguenin Hospital, Saint-Cloud, France
| | - Martial Caly
- Department of Biopathology, Curie Institute, PSL Research University, Paris, France
| | - Audrey Rapinat
- Genomics Platform, Translational Research Department, Curie Institute, PSL Research University, Paris, France
| | - David Gentien
- Genomics Platform, Translational Research Department, Curie Institute, PSL Research University, Paris, France
| | | | - Anne Schnitzler
- Pharmacogenomic Unit, Genetics Department, Curie Institute, PSL Research University, Paris, France
| | - François Lallemand
- Pharmacogenomic Unit, Genetics Department, Curie Institute, PSL Research University, Paris, France
| | - Elisabetta Marangoni
- Laboratory of Preclinical Investigations, Translational Research Department, Curie Institute, PSL Research University Paris, France
| | - Ivan Bièche
- Pharmacogenomic Unit, Genetics Department, Curie Institute, PSL Research University, Paris, France.,EA7331, Paris Descartes University, Sorbonne Paris Cité, Faculty of Pharmaceutical and Biological Sciences, Paris, France
| | - Céline Callens
- Pharmacogenomic Unit, Genetics Department, Curie Institute, PSL Research University, Paris, France
| |
Collapse
|
11
|
Coussy F, Bernard V, Lavigne M, Boulai A, Chateau-Joubert S, Dahmani A, Montaudon E, Reyes C, Botty RE, Pieron G, Laurent C, Melaabi S, Salomon AV, Bièche I, Marangoni E. Abstract 2973: A comprehensive panel of patient-derived xenografts representing the molecular heterogeneity and diversity of triple-negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-2973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease. Patients diagnosed with TNBC have a poor prognosis and identification of new biomarkers and therapeutic agents is a high priority. Patient-derived xenografts (PDX) are clinically relevant models that have emerged as important tool for the analysis of drug activity and predictive biomarker discovery. The purpose of this work was to analyze the molecular heterogeneity of a large panel of TNBC PDX with the perspective to test targeted therapy and to identify biomarkers of response.
Experimental Design: PDX of early-stage TNBC established from 2003 to 2016 (N=60) were analyzed by high-resolution array CGH and gene expression profiling (Cytoscan HD and Human Gene 1.1 ST arrays). Subtypes were identified with the tool TNBCtype (Chen et al., 2012) based on transcriptomic data. A targeted next-generation sequencing (NGS) of 100 genes (the top frequently mutated genes in breast cancer) was performed on Illumina HiSeq2500 sequencer. COSMIC, Tumorportal and cBioportal databases were used for the interpretation of genomic variants. Immunohistochemistry (IHC) and morphologic analysis of PDX were performed as compared to the corresponding patients' tumors. PDX carrying targetable genomic alterations in the PI3K/AKT/mTOR and MAPK signaling pathways were treated by specific inhibitors (selumetinib, BAY 80-6946 and PF-04691502).
Results: At the gene expression level, TNBC PDX represent all the different TNBC subtypes identified by the Lehmann classification. The frequency of the different TNBC subtypes was similar to the TGCA TNBC, except for the immunomodulatory subtype, underrepresented in PDX. Somatic pathologic mutations and copy number alterations were similar in PDX and TCGA TNBC patients. Among the top altered genes are TP53 and oncogenes and tumor suppressors of the PI3K/AKT/mTOR and MAPK pathways (including PIK3CA, AKT1, NF1 and NRAS/KRAS). At the histologic level, TNBC PDX were mainly composed of invasive ductal carcinoma of no special type, with some tumors being classified as apocrine or metaplastic carcinomas. Comparison with the original tumors show similar patterns (based on IHC analysis of CK5, CK8/18, CK14 and AR, FOXA1, EGFR and Ki67). In vivo efficacy experiments with PI3K and MAPK pathways inhibitors showed marked antitumor activity in PDX carrying genomic alterations of PIK3CA, AKT1 and NRAS, NF1 genes. Drug combination experiments are currently ongoing in PDX with simultaneous genomic alterations of PI3KCA and MAPK related genes.
Conclusions: TNBC PDX reproduce the molecular heterogeneity and diversity of TNBC patients. This large collection of PDX is a clinically relevant platform for drug testing, biomarker discovery and translational research.
Citation Format: Florence Coussy, Virginie Bernard, Marion Lavigne, Anais Boulai, Sophie Chateau-Joubert, Ahmed Dahmani, Elodie Montaudon, Cécile Reyes, Rania El Botty, Gaëlle Pieron, Cécile Laurent, Samia Melaabi, Anne Vincent Salomon, Ivan Bièche, Elisabetta Marangoni. A comprehensive panel of patient-derived xenografts representing the molecular heterogeneity and diversity of triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2973.
Collapse
|
12
|
Laloy E, Bréard E, Trapp S, Pozzi N, Riou M, Barc C, Breton S, Delaunay R, Cordonnier N, Chateau-Joubert S, Crochet D, Gouzil J, Hébert T, Raimbourg M, Viarouge C, Vitour D, Durand B, Ponsart C, Zientara S. Fetopathic effects of experimental Schmallenberg virus infection in pregnant goats. Vet Microbiol 2017; 211:141-149. [PMID: 29102110 DOI: 10.1016/j.vetmic.2017.10.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Revised: 10/05/2017] [Accepted: 10/06/2017] [Indexed: 10/18/2022]
Abstract
Schmallenberg virus (SBV) is an emerging virus responsible for congenital malformations in the offspring of domestic ruminants. It is speculated that infection of pregnant dams may also lead to a significant number of unrecognized fetal losses during the early period of gestation. To assess the pathogenic effects of SBV infection of goats in early pregnancy, we inoculated dams at day 28 or 42 of gestation and followed the animals until day 55 of gestation. Viremia in the absence of clinical signs was detected in all virus-inoculated goats. Fetal deaths were observed in several goats infected at day 28 or 42 of gestation and were invariably associated with the presence of viral genomic RNA in the affected fetuses. Among the viable fetuses, two displayed lesions in the central nervous system (porencephaly) in the presence of viral genome and antigen. All fetuses from goats infected at day 42 and the majority of fetuses from goats infected at day 28 of gestation contained viral genomic RNA. Viral genome was widely distributed in these fetuses and their respective placentas, and infectious virus could be isolated from several organs and placentomes of the viable fetuses. Our results show that fetuses of pregnant goats are susceptible to vertical SBV infection during early pregnancy spanning at least the period between day 28 and 42 of gestation. The outcomes of experimental SBV infection assessed at day 55 of gestation include fetal mortalities, viable fetuses displaying lesions of the central nervous system, as well as viable fetuses without any detectable lesion.
Collapse
Affiliation(s)
- Eve Laloy
- Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Unité d'anatomie pathologique, 7 avenue du Général de Gaulle, 94704 Maisons-Alfort, France; Université Paris-Est, ANSES, Laboratoire de Santé Animale, UMR 1161 Virologie ANSES-INRA-ENVA, 14 rue Pierre et Marie Curie, 94704 Maisons-Alfort, France.
| | - Emmanuel Bréard
- Université Paris-Est, ANSES, Laboratoire de Santé Animale, UMR 1161 Virologie ANSES-INRA-ENVA, 14 rue Pierre et Marie Curie, 94704 Maisons-Alfort, France
| | - Sascha Trapp
- INRA Centre Val de Loire, UMR 1282 Infectiologie et Santé Publique, 37380 Nouzilly, France; Université François Rabelais de Tours, UMR 1282 Infectiologie et Santé Publique, 37000 Tours, France
| | - Nathalie Pozzi
- LNCR, Laboratoire national de contrôle des reproducteurs, 13, rue Jouët, 94703 Maisons-Alfort, France
| | - Mickaël Riou
- INRA Centre Val de Loire, UE-1277 Plateforme d'Infectiologie Expérimentale, secteur 3, route de Crotelles, 37380 Nouzilly, France
| | - Céline Barc
- INRA Centre Val de Loire, UE-1277 Plateforme d'Infectiologie Expérimentale, secteur 3, route de Crotelles, 37380 Nouzilly, France
| | - Sylvain Breton
- INRA Centre Val de Loire, UE-1277 Plateforme d'Infectiologie Expérimentale, secteur 3, route de Crotelles, 37380 Nouzilly, France
| | - Rémi Delaunay
- INRA Centre Val de Loire, UE-1277 Plateforme d'Infectiologie Expérimentale, secteur 3, route de Crotelles, 37380 Nouzilly, France
| | - Nathalie Cordonnier
- Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Unité d'anatomie pathologique, 7 avenue du Général de Gaulle, 94704 Maisons-Alfort, France; Université Paris-Est, ANSES, Laboratoire de Santé Animale, UMR 1161 Virologie ANSES-INRA-ENVA, 14 rue Pierre et Marie Curie, 94704 Maisons-Alfort, France
| | - Sophie Chateau-Joubert
- Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Unité d'anatomie pathologique, 7 avenue du Général de Gaulle, 94704 Maisons-Alfort, France
| | - Didier Crochet
- INRA Centre Val de Loire, UE-1277 Plateforme d'Infectiologie Expérimentale, secteur 3, route de Crotelles, 37380 Nouzilly, France
| | - Julie Gouzil
- Université Paris-Est, ANSES, Laboratoire de Santé Animale, UMR 1161 Virologie ANSES-INRA-ENVA, 14 rue Pierre et Marie Curie, 94704 Maisons-Alfort, France
| | - Typhaine Hébert
- Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Unité d'anatomie pathologique, 7 avenue du Général de Gaulle, 94704 Maisons-Alfort, France
| | - Maxime Raimbourg
- LNCR, Laboratoire national de contrôle des reproducteurs, 13, rue Jouët, 94703 Maisons-Alfort, France
| | - Cyril Viarouge
- Université Paris-Est, ANSES, Laboratoire de Santé Animale, UMR 1161 Virologie ANSES-INRA-ENVA, 14 rue Pierre et Marie Curie, 94704 Maisons-Alfort, France
| | - Damien Vitour
- Université Paris-Est, ANSES, Laboratoire de Santé Animale, UMR 1161 Virologie ANSES-INRA-ENVA, 14 rue Pierre et Marie Curie, 94704 Maisons-Alfort, France
| | - Benoît Durand
- Université Paris-Est, ANSES, Laboratoire de Santé Animale, 14 rue Pierre et Marie Curie, 94700 Maisons-Alfort, France
| | - Claire Ponsart
- LNCR, Laboratoire national de contrôle des reproducteurs, 13, rue Jouët, 94703 Maisons-Alfort, France
| | - Stéphan Zientara
- Université Paris-Est, ANSES, Laboratoire de Santé Animale, UMR 1161 Virologie ANSES-INRA-ENVA, 14 rue Pierre et Marie Curie, 94704 Maisons-Alfort, France
| |
Collapse
|
13
|
Tury S, Vacher S, Becette V, Assayag F, Chateau-Joubert S, Servely JL, Marangoni E, Bièche I, Callens C. Abstract 2031: Antitumoral synergy of iron chelators and chemotherapies in triple-negative breast cancer cell lines and patient-derived xenograft. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-2031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Tumor cells present an iron metabolic disorder with high proliferation rate, increased iron storage (ferritin and Labile Iron Pool - LIP) and high sensibility to iron deprivation, which could be a therapeutic target. Anticancer effect of iron chelators deferoxamine (DFO) and deferasirox (DFX) has been revealed in several types of cancers. In breast cancer (BC), the development of new therapeutic approaches is urgently needed for triple negative (TN) subtype which presents poor prognosis and lacks targeting therapy. We investigated the therapeutic potential of iron chelators combined with chemotherapeutic agents in TNBC cell lines and patient-derived xenografts (PDX).
Methods: Anticancer effects of iron chelators combined with chemotherapeutic agents (doxorubicin, cisplatin or carboplatin) were evaluated in vitro in 4 TNBC cell lines by MTT assay, annexin V/PI staining and assessment of caspase 3/7 activity. Assessment of LIP, transferrin receptor 1 (TfR1) expression level, Reactive Oxygen Species (ROS) production and mitochondrial membrane potential variations were performed by flow cytometry, and ELISA assay for ferritin level. The activity of DFX alone or combined with doxorubicin/cyclophosphamide (AC) was tested in the HBCx-10 TNBC PDX selected because of its relapse to AC. Iron homeostasis, hypoxia and PI3K pathway were analyzed by immunohistochemistry (IHC) and Western-blot in both cell lines and PDX tumors. In DFX+/-AC treated and untreated tumors, induction of apoptosis was performed by TUNEL assay and a transcriptome analysis is ongoing.
Results: Iron chelators acted in synergy effect with three chemotherapies in all cell lines which were tested to inhibit cell proliferation and induce apoptosis. Chelators increased cytotoxicity until 60% compared to chemotherapies alone. In all cell lines, chelators treatment increased TfR1 expression level and decreased LIP and ferritin. Furthermore, down-regulation of PI3K pathway, hypoxia, mitochondrial membrane potential, and the production increasing of ROS were observed. In HBCx-10 PDX, a trend for antitumoral activity of DFX alone was observed (p=0.09) at the end of the experiment (day 81). A significant difference of Relative Tumor Volume (RTV) was observed since day 18 between the AC group and the DFX+AC group (tumor growth inhibition: 37 to 61%, tumor growth delay: 10 to 14 days, 0.005<p<0.04). Same as the observing in vitro, modulations of PI3K pathway and hypoxia are involved in this antitumoral synergy. Except neutropenia (due to chemotherapy), no other hematologic toxicity was observed in both AC and DFX+AC groups.
Conclusions: Iron chelators may increase the effectiveness of conventional chemotherapies for TNBC treatments. This antitumoral synergy involves PI3K pathway downregulation, ROS production and decrease mitochondrial membrane potential.
Citation Format: Sandrine Tury, Sophie Vacher, Véronique Becette, Franck Assayag, Sophie Chateau-Joubert, Jean-Luc Servely, Elisabetta Marangoni, Ivan Bièche, Céline Callens. Antitumoral synergy of iron chelators and chemotherapies in triple-negative breast cancer cell lines and patient-derived xenograft [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2031. doi:10.1158/1538-7445.AM2017-2031
Collapse
|
14
|
Marangoni E, Hatem R, Labiod D, Chateau-Joubert S, El Botty R, Servely JL, De Plater L, Bièche I. Abstract 1687: Vandetanib as a potential new treatment for ER negative breast cancers. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-1687] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Recent studies have shown that the receptor tyrosine kinase RET is involved in the biology of ER positive breast cancers and in the response to endocrine treatment, but its role in ER negative tumors is unknown. Here we investigated the expression of RET in BC patients tumors and patient-derived xenografts (PDX) and evaluated the therapeutic potential of Vandetanib in ER negative BC PDX.
Methods: RET mRNA expression was analyzed in BC of 446 patients and 57 PDX by RT-PCR analysis. The activity of Vandetanib, a tyrosine kinase inhibitor targeting RET, EGFR and VEGFR2, was tested in three PDX of triple-negative breast cancer (TNBC) and one PDX of HER2+ BC with different levels of RET expression. Protein expression of P-RET, RET, EGFR, P-EGFR and c-KIT were determined by immunohistochemistry (IHC). Analyses of PI3K and MAPK pathways and angiogenesis were performed by IHC and RT-PCR in both untreated and Vandetanib-treated tumors.
Results: In both clinical samples and PDX, elevated levels of RET were found in ER+ and HER2+ tumors, and in a subgroup of TNBC tumors. In the HBCx5 (HER2+) and HBCx24 (TNBC) PDX, both with RET over-expression, treatment by Vandetanib resulted in tumor growth inhibition (TGI) of 90% and 98%, respectively. In both models, tumor regressions were observed in 50% of xenografts. The effect of Vandetanib was associated to a marked inhibition of RET phosphorylation. To determine whether the lack of RET over-expression was associate to Vandetanib resistance, we treated two additional TNBC PDX with low and no expression of RET: HBCx4B and HBCx14. In these models, treatment by Vandetanib still inhibited tumor growth with a TGI of 85%. Tumor regressions were registered in 42% of animals in the PDX model with low expression of RET (HBCx4B), while no tumor regression were observed in HBCx14. IHC analyses showed an over-expression of EGFR in the HBCx4B xenograft and inhibition of EGFR phosphorylation in treated tumors, suggesting that tumor response to Vandetanib could depend on EGFR inhibition in this tumor. Further analyses of treated tumors revealed a decreased expression of phospho-ERK in the 4 PDX models, indicating inhibition of MAPK pathway, while the phosphorylation status of the PI3K pathway markers S6 and 4EBP1 was unchanged. Finally, treatment by Vandetanib decreased expression of murine Vegf receptors and the endothelial marker Cd31 in the 4 PDX tested, indicating angiogenesis inhibition.
Conclusions: Treatment by Vandetanib resulted in strong tumor growth inhibition in ER negative PDX with over-expression of RET. This effect was associated to inhibition of RET phosphorylation and MAPK pathway and decreased tumor vascularization. The lack of RET over-expression did not predict Vandetanib resistance, and over-expression of EGFR was also associated to a marked tumor response. These preclinical results suggest that Vandetanib treatment could be useful for patients with ER negative breast cancers expressing Vandetanib's targets.
Citation Format: Elisabetta Marangoni, Rana Hatem, Dalila Labiod, Sophie Chateau-Joubert, Rania El Botty, Jean-Luc Servely, Ludmilla De Plater, Ivan Bièche. Vandetanib as a potential new treatment for ER negative breast cancers. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1687. doi:10.1158/1538-7445.AM2015-1687
Collapse
|
15
|
Nunes M, Vrignaud P, Vacher S, Richon S, Lièvre A, Cacheux W, Weiswald LB, Massonnet G, Chateau-Joubert S, Nicolas A, Dib C, Zhang W, Watters J, Bergstrom D, Roman-Roman S, Bièche I, Dangles-Marie V. Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. Cancer Res 2015; 75:1560-6. [PMID: 25712343 DOI: 10.1158/0008-5472.can-14-1590] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2014] [Accepted: 02/06/2015] [Indexed: 11/16/2022]
Abstract
Development of targeted therapeutics required translationally relevant preclinical models with well-characterized cancer genome alterations. Here, by studying 52 colorectal patient-derived tumor xenografts (PDX), we examined key molecular alterations of the IGF2-PI3K and ERBB-RAS pathways and response to cetuximab. PDX molecular data were compared with that published for patient colorectal tumors in The Cancer Genome Atlas. We demonstrated a significant pattern of mutual exclusivity of genomic abnormalities in the IGF2-PI3K and ERBB-RAS pathways. The genomic anomaly frequencies observed in microsatellite stable PDX reproduce those detected in nonhypermutated patient tumors. We found frequent IGF2 upregulation (16%), which was mutually exclusive with IRS2, PIK3CA, PTEN, and INPP4B alterations, supporting IGF2 as a potential drug target. In addition to maintaining the genomic and histologic diversity, correct preclinical models need to reproduce drug response observed in patients. Responses of PDXs to cetuximab recapitulate also clinical data in patients, with partial or complete response in 15% (8 of 52) of PDXs and response strictly restricted to KRAS wild-type models. The response rate reaches 53% (8 of 15) when KRAS, BRAF, and NRAS mutations are concomitantly excluded, proving a functional cross-validation of predictive biomarkers obtained retrospectively in patients. Collectively, these results show that, because of their clinical relevance, colorectal PDXs are appropriate tools to identify both new targets, like IGF2, and predictive biomarkers of response/resistance to targeted therapies.
Collapse
Affiliation(s)
- Manoel Nunes
- Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Vitry-sur-Seine, France. Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Cambridge, Massachusetts
| | - Patricia Vrignaud
- Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Vitry-sur-Seine, France. Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Cambridge, Massachusetts
| | - Sophie Vacher
- Service de Génétique, Hôpital Institut Curie, Paris, France
| | - Sophie Richon
- IFR71, Faculté de Sciences Biologiques et Pharmaceutiques, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Astrid Lièvre
- Département d'Oncologie médicale, Hôpital Institut Curie, Paris, France. Université de Versailles Saint-Quentin en Yvelines, Faculté des Sciences Biologiques, Versailles, France
| | - Wulfran Cacheux
- Département d'Oncologie médicale, Hôpital Institut Curie, Paris, France
| | - Louis-Bastien Weiswald
- IFR71, Faculté de Sciences Biologiques et Pharmaceutiques, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Gerald Massonnet
- Recherche Translationnelle, Centre de Recherche, Institut Curie, Paris, France
| | - Sophie Chateau-Joubert
- France Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, Unité d'Anatomie Pathologique, Maisons-Alfort, France
| | - André Nicolas
- Département de Pathologie, Hôpital Institut Curie, Paris, France
| | - Colette Dib
- Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Vitry-sur-Seine, France. Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Cambridge, Massachusetts
| | - Weidong Zhang
- Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Vitry-sur-Seine, France. Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Cambridge, Massachusetts
| | - James Watters
- Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Vitry-sur-Seine, France. Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Cambridge, Massachusetts
| | - Donald Bergstrom
- Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Vitry-sur-Seine, France. Translational and Experimental Medicine, Sanofi Oncology, Sanofi, Cambridge, Massachusetts
| | - Sergio Roman-Roman
- Recherche Translationnelle, Centre de Recherche, Institut Curie, Paris, France
| | - Ivan Bièche
- Service de Génétique, Hôpital Institut Curie, Paris, France. IFR71, Faculté de Sciences Biologiques et Pharmaceutiques, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Virginie Dangles-Marie
- IFR71, Faculté de Sciences Biologiques et Pharmaceutiques, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. Recherche Translationnelle, Centre de Recherche, Institut Curie, Paris, France.
| |
Collapse
|
16
|
Marangoni E, Hatem R, Botty RE, Plater LD, Labiod D, Vacher S, Chateau-Joubert S, Bièche I. Abstract 4499: Activation of PI3-kinase pathway and tumor response to everolimus in patient-derived xenografts of triple-negative breast cancer. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-4499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Patients with triple-negative breast cancer (TNBC) have a poor prognosis and targeted therapies are lacking. Recent studies performed on patients tumors showed and increased activity of the phosphatidylinositol 3-kinase (PI3K) pathway in TNBC. PI3K pathway is critical for cell growth, survival, and angiogenesis. Everolimus is a mTOR inhibitor recently showed to increase survival of patients with metastatic luminal breast cancer. The objectives of this work were to analyze the PI3K activation status in a large cohort of patient-derived xenografts (PDX) of TNBC and to investigate the therapeutic potential of mTOR inhibition.
Experimental procedures: this study included a panel of 32 TNBC PDX models previously described (Marangoni et al 2007). Expression of AKT, P-AKT, P-mTOR, S6, P-S6, P-4EBP1, PTEN and INPP4B was analyzed by WB and IHC. Mutations of PIK3CA (exons 9 and 20), PIK3R1 (exons 11-15), and AKT1 (exon 4) were detected by sequencing of cDNA fragments obtained by RT-PCR amplification. The efficacy of the mTOR inhibitor everolimus was investigated in vivo on 10 PDX models with different expressions and mutational status of PI3K markers.
Results: INPP4B protein expression was lost in 56% of tumors (n=18) and expressed at low levels in 31% of models, while only 2 models displayed a marked expression. PTEN expression was lost in 78% of tumors. Thirteen PDX models (40%) displayed a concomitant loss of both INPP4B and PTEN proteins. In 67% of tumors, the ratio between phosphorylated and unphosphorylated AKT was greater than 1. S6 was found to be phosphorylated in the great majority of tumors. PI3KCA and AKT1 genes were mutated only in 1 and 2 tumors, respectively. On the 10 PDX models treated with everolimus, 6 models responded to treatment with a tumor growth inhibition (TGI) comprised between 60% and 80%. Four models were classified as resistant or low responder (TGI<50%). Preliminary analysis of treated tumors from 6 models indicates increased level of P-AKT (feedback loop) to occur only in responder models, while inhibition of S6 phosphorylation occurred in treated tumors from both responder and resistant models. Finally, expression of INPP4B or PTEN alone did not predict for tumor response, while a P-AKT/AKT ratio greater than 1 predicted response to everolimus (p<0.05, Fisher's exact test).
Conclusions: the majority of TNBC PDX models showed loss of PTEN or INPP4B proteins or both, associated with activation of PI3K pathway. Preliminary results obtained from 10 PDX models indicate that mTOR targeting resulted in tumor growth inhibition in several models with AKT phosphorylation. Additional TNBC models will be tested in order to search for robust predictive biomarkers. This large panel of characterized PDX of TNBC models represents a clinical relevant tool to investigate the activity of PI3K-AKT-mTOR inhibitors and identify predictive biomarkers.
Citation Format: Elisabetta Marangoni, Rana Hatem, Rania El Botty, Ludmilla De Plater, Dalila Labiod, Sophie Vacher, Sophie Chateau-Joubert, Ivan Bièche. Activation of PI3-kinase pathway and tumor response to everolimus in patient-derived xenografts of triple-negative breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4499. doi:10.1158/1538-7445.AM2014-4499
Collapse
|
17
|
Cottu P, Bièche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Servely JL, Fontaine JJ, Decaudin D, Pierga JY, Roman-Roman S, Marangoni E. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts. Clin Cancer Res 2014; 20:4314-25. [PMID: 24947930 DOI: 10.1158/1078-0432.ccr-13-3230] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Patients with luminal breast cancer (LBC) often become endocrine resistant over time. We investigated the molecular changes associated with acquired hormonoresistances in patient-derived xenografts of LBC. EXPERIMENTAL DESIGN Two LBC xenografts (HBCx22 and HBCx34) were treated with different endocrine treatments (ET) to obtain xenografts with acquired resistances to tamoxifen (TamR) and ovariectomy (OvaR). PI3K pathway activation was analyzed by Western blot analysis and IHC and responses to ET combined to everolimus were investigated in vivo. Gene expression analyses were performed by RT-PCR and Affymetrix arrays. RESULTS HBCx22 TamR xenograft was cross-resistant to several hormonotherapies, whereas HBCx22 OvaR and HBCx34 TamR exhibited a treatment-specific resistance profile. PI3K pathway was similarly activated in parental and resistant xenografts but the addition of everolimus did not restore the response to tamoxifen in TamR xenografts. In contrast, the combination of fulvestrant and everolimus induced tumor regression in vivo in HBCx34 TamR, where we found a cross-talk between the estrogen receptor (ER) and PI3K pathways. Expression of several ER-controlled genes and ER coregulators was significantly changed in both TamR and OvaR tumors, indicating impaired ER transcriptional activity. Expression changes associated with hormonoresistance were both tumor and treatment specific and were enriched for genes involved in cell growth, cell death, and cell survival. CONCLUSIONS PDX models of LBC with acquired resistance to endocrine therapies show a great diversity of resistance phenotype, associated with specific deregulations of ER-mediated gene transcription. These models offer a tool for developing anticancer therapies and to investigate the dynamics of resistance emerging during pharmacologic interventions. Clin Cancer Res; 20(16); 4314-25. ©2014 AACR.
Collapse
Affiliation(s)
- Paul Cottu
- Departments of Medical Oncology and Laboratory of Preclinical Investigation, Translational Research Department
| | | | - Franck Assayag
- Laboratory of Preclinical Investigation, Translational Research Department
| | - Rania El Botty
- Laboratory of Preclinical Investigation, Translational Research Department
| | | | - Aurélie Thuleau
- Laboratory of Preclinical Investigation, Translational Research Department
| | - Thomas Bagarre
- Laboratory of Preclinical Investigation, Translational Research Department
| | - Benoit Albaud
- Affymetrix Platform, Translational Research Department
| | | | - David Gentien
- Affymetrix Platform, Translational Research Department
| | | | - Vonick Sibut
- Bioinformatics Unit, Inserm U900 Mines ParisTech
| | | | | | - Jean-Luc Servely
- INRA, Phase Department; Pathology Department, National Veterinary School of Alfort, Maisons Alfort, France
| | | | - Didier Decaudin
- Departments of Medical Oncology and Laboratory of Preclinical Investigation, Translational Research Department
| | | | | | | |
Collapse
|
18
|
Cottu PH, Bièche I, de la Grange P, Gentien D, Assayag F, Thuleau A, El-Botty R, Chateau-Joubert S, Huerre M, Hatem R, Richon S, Slimane K, Marangoni E. Abstract P5-09-07: Identification of resistance-specific gene expression signatures in a breast cancer patient-derived xenograft with acquired resistance to different endocrine therapies. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-09-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Acquired resistance to endocrine treatments (ET) occurs in more than 70% of cases of luminal breast cancer (LBC). We used patient derived xenografts (PDX) models of LBC to study molecular changes associated with acquired resistance to different ET modalities.
Methods:
A PDX model of LBC, established from an early stage BRCA2-mutated breast cancer, was treated with different ET (tamoxifen, fulvestrant, oophorectomy and letrozole) during several months. Tumors escaping to therapies were re-engrafted and maintained under therapy. ET-resistant and parental hormono-responders tumors were analyzed with immunohistochemistry (IHC), RT-PCR and Affymetrix Gene Expression Arrays. Hormono-resistant tumors were additionally studied for their in vivo response to ET, mTOR and PARP inhibitors.
Results:
From the initially ET sensitive HBCx22 xenograft model (Cottu, BCRT 2012) two resistant models were obtained respectively to tamoxifen (HBCx22-TamR) and to estrogen deprivation (HBCx22-OvaR). Unsupervised clustering of gene expression showed a clear cut separation between parental, TamR and OvaR tumors. Genes differentially expressed in TamR and OvaR tumors compared to parental HBCx22 were only partially overlapping. Up-Regulated genes in both TamR and OvaR tumors (n = 302) were involved in response to wounding, nucleotide metabolism, immune system, adhesion and cell growth. Biological Processes (BP) specifically deregulated in OvaR tumors (n = 380) included embryonic development, antigen presentation, amino acid and lipid metabolism. The top BP specifically regulated in TamR tumors (n = 1059) were response to estrogen and steroid hormones, TGF-b signaling, hypoxia, regulation of cell proliferation, with several strongly up-regulated genes of the histone clusters 1 and 3. Ingenuity Transcription Factor Analysis predicted activation of NFKB, SP1, AP-1 and JUN, and inhibition of ESR1. RT-PCR and IHC analyses confirmed the down regulation of ER controlled genes in the TamR tumors. Expression of ER co-regulators determined by RT-PCR showed that GREB1 was strongly reduced in TamR, while PBX1, GATA3 and FOXA1 were inhibited in OvaR. IHC analysis showed a loss of PTEN expression in HBCx22, with high levels of p-AKT and p-RPS6 in both parental and TamR and OvaR tumors. In vivo ET showed that the TamR xenograft was resistant to all modalities of ET, while OvaR was resistant to estrogen deprivation while retaining some sensitivity to tamoxifen and fulvestrant. Treatment with the mTOR inhibitor RAD001 arrested tumor growth but did not show any additive effect when combined to ET in TamR or OvaR tumors. Conversely, the combination of RAD001 with Olaparib was highly synergistic and induced complete tumor response in 70% of mice.
Conclusions:
According to the therapeutic selection, tumors derived from a PDX model of ER+ breast cancer show specific resistance patterns and gene expression profiles including disruption in the ER transcriptional program. The analysis of additional resistant tumors established from a second ER+ PDX will be presented at the meeting.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-09-07.
Collapse
Affiliation(s)
- PH Cottu
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - I Bièche
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - P de la Grange
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - D Gentien
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - F Assayag
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - A Thuleau
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - R El-Botty
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - S Chateau-Joubert
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - M Huerre
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - R Hatem
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - S Richon
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - K Slimane
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - E Marangoni
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| |
Collapse
|
19
|
El Botty R, Cottu P, Assayag F, de la Grange P, Gentien D, Thuleau A, Vacher S, Chateau-Joubert S, Bièche I, Marangoni E. Abstract C174: Establishment of luminal breast cancer patient-derived xenografts with acquired resistance to both hormonotherapy and everolimus. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-c174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The addition of everolimus (Rad) to endocrine therapies (ET) in luminal advanced breast cancers has shown to increase overall survival in randomized studies. However drug resistance is an emerging problem and most patients eventually experience progression of disease. We aimed to establish and characterize patient-derived xenografts (PDX) of luminal breast cancers with acquired resistance in vivo to both ET and Rad. Two PDX xenografts (HBCx22 and HBCx34), established from early stage ER+ breast cancers, were treated in vivo with different ET (tamoxifen, fulvestrant, ovariectomy and letrozole) during 12 months and tumors escaping to therapies were re-engrafted and maintained under treatment. Four hormono-resistant (HR) xenografts were established, 2 resistant to Tamoxifen (HBCx22TamR and HBCx34TamR) and 2 resistant to ovariectomy (HBCx22OvaR and HBCx34OvaR). Expression of estrogen receptor (ER) was maintained, while expression of several ER-controlled genes (MYB, PS2 and PR) was decreased in HR tumors indicating modifications of ER transcriptional activity. The expression of ER co-regulators was additionally studied: GREB1 was reduced specifically in TamR, while FOXA1 were increased specifically in TamR. Expression analysis of P-AKT, P-mTOR and P-S6 showed similar levels of PI3 kinase pathway activation between parental and HR xenografts. Gene expression profiling, performed with Affymetrix Gene Expression Arrays, showed that genes differentially expressed in TamR and OvaR tumors were only partially overlapping, suggesting treatment-specific mechanisms of hormono-resistance. In addition, TamR and OvaR signatures were tumor-specific. Gene ontology enrichment and pathway analyses of gene expression datasets will be presented at the meeting. HR xenografts were then treated with Rad alone and combined to ET. In HBCx22OvaR and TamR, resistant to all ET, treatment with Rad arrested tumor growth in vivo but did not show any additive effect when combined to ET. Conversely, the HBCx34TamR model was still responding to fulvestrant, and the combination Rad+Fulvestrant resulted in tumor regressions. In the HBCx34TamR xenograft, tumor escape to Rad treatment occurred in one mouse after 8 months of continuous treatment. The tumor was re-engrafted and maintained as tumorgraft resistant to both tamoxifen and Rad (HBCx34Tam-RadR). Western blot and IHC studies showed that mTOR signaling was still inhibited in this tumor, but it was associated to MAP kinase activation and increased IGF-1R expression. In conclusion, we have developed PDX models of luminal breast cancer with cross-resistance to ET and everolimus in vivo. These models provide a valuable preclinical tool to investigate molecular mechanisms of acquired resistance and to test new targeted therapies and new combinations in patients’ tumors.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C174.
Citation Format: Rania El Botty, Paul Cottu, Franck Assayag, Pierre de la Grange, David Gentien, Aurélie Thuleau, Sophie Vacher, Sophie Chateau-Joubert, Ivan Bièche, Elisabetta Marangoni. Establishment of luminal breast cancer patient-derived xenografts with acquired resistance to both hormonotherapy and everolimus. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C174.
Collapse
|
20
|
Marangoni E, Labiod D, Assayag F, El Botty R, Hatem R, Richon S, Chateau-Joubert S, Carlus M, Bonsang-Kitzis H, Pinheiro A, Laurent C, Bièche I, Reyal F. Abstract A9: Establishment and characterization of residual breast cancer patient-derived xenografts resistant to neo-adjuvant therapy. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-a9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In HER2 positive and triple-negative breast cancer subgroups, residual disease after neoadjuvant therapy is associated with higher risk of metastatic recurrence compared to patients achieving a pathological complete response. Residual tumor analysis after neoadjuvant treatment is a major and under-explored field to identify resistance mechanisms.
To develop patient-derived xenografts (PDX) of residual breast cancer we started a program of residual tumor engraftment in nude mice, following the same procedures previously published for PDX of human breast cancer (Marangoni et al, 2007 and Reyal et al, 2012).
Methods: 26 residual breast tumors and 2 residual metastatic axillary lymph nodes were engrafted in swiss nude mice immediately after surgery. Expression of Ki67, HER2, PTEN, P-AKT, P-S6, MET, RET and KIT were analyzed in xenografts by immunohistochemistry, western blot and RT-PCR analyses. Brain, lungs, liver and bones of xenografts were systematically formalin-fixed to search for human metastasis. The in vivo drug response of established xenografts was determined for the following treatments: adryamicin+cyclophosphamide (AC), docetaxel, capecitabine, cisplatin, irinotecan, everolimus, trastuzumab and lapatinib (for the HER2+ PDX). PDX tumors were additionally mechanically dissociated to establish cell lines.
Results: Seven PDX were established (tumor take of 25%), 5 triple-negative and 2 HER2+. Six out of seven PDX were metastatic in the lungs. Two xenografts were established from lymph node metastasis. The in vivo drug responses were concordant with the response to neo-adjuvant treatments in patients. Histological analyses showed that xenografts’ tumors recapitulated the patients’ tumor morphology. Residual tumor xenografts expressed high level of Ki67 protein and tumor latency during the first tumor passages was found to be shorter when compared to tumor latency of non pre-treated breast cancers. In 5/5 triple-negative breast cancer PDX the PTEN protein was lost and the PI3 kinase pathway activated. The mTOR inhibitor Everolimus was tested in 2 triple-negative PDX: one was resistant and one was responding, with a tumor growth inhibition of 80%. Triple-negative PDX show expression of “druggable” tyrosin kinase receptors (MET, RET, KIT) providing relevant models to test new target therapies in these models. One cell line was established from a highly metastatic triple-negative breast cancer xenograft. When re-injected into mice, the cell line was tumorigenic, however the tumor architecture was changed and the xenograft was not metastatic.
Conclusions: we have established a panel of metastatic PDX models of breast cancer resistant to neo-adjuvant therapies. These models provide a valuable preclinical tool to investigate mechanisms of resistance to neo-adjuvant treatments and for the preclinical testing of new targeted agents.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A9.
Citation Format: Elisabetta Marangoni, Dalila Labiod, Franck Assayag, Rania El Botty, Rana Hatem, Sophie Richon, Sophie Chateau-Joubert, Marine Carlus, Hélène Bonsang-Kitzis, Alice Pinheiro, Cécile Laurent, Ivan Bièche, Fabien Reyal. Establishment and characterization of residual breast cancer patient-derived xenografts resistant to neo-adjuvant therapy. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A9.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Marine Carlus
- 3National Veterinary School of Alfort, Maisons-Alfort, France
| | | | | | | | | | | |
Collapse
|
21
|
Cottu PH, Bagarre T, Fontaine JJ, Assayag F, Richon S, Chateau-Joubert S, Thuleau A, de Cremoux P, Slimane K, Decaudin D, Vincent-Salomon A, Bièche I, Marangoni E. Abstract 85: Endocrine resistant luminal breast cancer xenografts are powerful models for the analysis of sensitivity to endocrine and everolimus treatments . Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Activation of the PI3K pathway is associated with resistance to endocrine treatments (ET) in luminal breast cancer (LBC). Everolimus, an mTOR inhibitor, has been approved in combination with exemestane in endocrine resistant breast tumors. However, no definite signature of ET resistance or predictive factors of sensitivity to everolimus (EVE) treatment have been evidenced so far. In order to further decipher these molecular patterns, we used patient derived LBC xenografts (LBC-PDX) treated with various ET and EVE based combinations.
Methods. 3 LBC-PDX (named HBCx-3, HBCx-21 and HBCx-34) were treated with ET during several months to establish hormono-resistant (HR) xenografts. Both parental and HR models were treated by tamoxifen, estrogen deprivation, fulvestrant, EVE alone, and EVE combined with all three ET modalities. Tissue Micro Arrays from control and treated tumor samples were generated for IHC analyses. RT-PCR analyses were conducted on genes related to proliferation, ER, PI3K, IGF-1R and angiogenesis pathways.
Results. In primary PDX, ET showed a poor level of sensitivity for HBCx-3 and a high and sustained efficacy of ER targeting and/or ER deprivation for HBCx-21 and HBCx-34 tumors. In vivo resistance to ET was confirmed in all HR variants with tumor growth rates faster than parental xenografts. ER expression was conserved in HR tumors, but expression of the ER-responsive genes PS2, PR and MYB was strongly decreased, indicating impaired ER transcriptional activity. Acquired resistance to tamoxifen and ovariectomy was also associated to a strong decrease of IGF-1R signaling in HBCx-21, and was related to higher P-AKT expression, although P-pS6 was highly expressed in both sensitive and resistant tumors. Furthermore, in vivo experiments showed that EVE alone was highly efficient in all models independently of P-AKT expression/PTEN loss. EVE combined with fulvestrant yielded the most complete and durable tumor growth inhibition. In HBCx-3, proliferation and pS6 levels were markedly decreased only by the EVE-fulvestrant combination. In HBCx-21 and HBCx-34 HR models, EVE-based treatments decreased proliferation, expression of angiogenesis markers, as well as P-pS6 expression with no variation in (P-)AKT nor (P-)mTOR levels. A high IGF-1R protein expression was found only in the HBCx-34 TAM-R tumor, which was strongly decreased in the fulvestrant-treated tumors.
Conclusions. LBC-PDX with confirmed HR status have been established and may serve as models to study alternate therapies. Of note, in the HBCx-21 and -34 models, activation of the PI3K pathway is poorly correlated with baseline sensitivity to ET, suggesting other pathways of resistance. EVE alone is highly efficient in all settings, and combination with fulvestrant is promising at the in vivo and molecular levels. Proteomic, genomic and gene expression studies are ongoing.
Citation Format: Paul H. Cottu, Thomas Bagarre, Jean-Jacques Fontaine, Franck Assayag, Sophie Richon, Sophie Chateau-Joubert, Aurélie Thuleau, Patricia de Cremoux, Khemaies Slimane, Didier Decaudin, Anne Vincent-Salomon, Ivan Bièche, Elisabetta Marangoni. Endocrine resistant luminal breast cancer xenografts are powerful models for the analysis of sensitivity to endocrine and everolimus treatments . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 85. doi:10.1158/1538-7445.AM2013-85
Collapse
Affiliation(s)
| | | | | | | | - Sophie Richon
- 3Faculté de Pharmacie Paris Descartes, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Laloy E, Chateau-Joubert S, El Mrini M, Rakotovao F, Carlus M, Reyes-Gomez E, Delfosse V, Cordonnier N. A Case of Scrotal Leiomyosarcoma in a Dog. J Comp Pathol 2013. [DOI: 10.1016/j.jcpa.2012.11.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Cottu PH, Bagarre T, Assayag F, Bièche I, Chateau-Joubert S, Fontaine JJ, Decaudin D, Slimane K, Vincent-Salomon A, Marangoni E. Abstract P6-04-14: Targeting the PI3K/mTOR pathway in patient-derived xenograft models of endocrine resistant luminal breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-04-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Most ER+ tumors will eventually escape endocrine treatments. PI3K/mTOR pathway targeting has improved clinical results in endocrine treatments resistant (ETR) patients, however with unsustained responses. Our laboratory has developed several models of ETR luminal breast cancer (LBC) patient derived xenografts (PDX) suitable for biological studies (Cottu et al, AACR 2012 & IMPAKT 2012). The aims of the present study were 1) to analyze the biological factors associated with acquired ETR in relevant models of LBC; 2) to determine the therapeutic interest of combining everolimus with different ET models resistant to different endocrine treatments (ET).
Methods. Implementation of LBC models has been reported (Cottu et al, BCRT 2012). ETR models were derived by selecting tumors growing under continuous ET, subsequently re-engrafted and rechallenged with endocrine therapies (tamoxifen, letrozole, fulvestrant), and with everolimus alone and combined with ETs. When possible, initial sensitive tumors were simultaneously treated with the same protocols. At progression, or after at least 120 days of continuous therapies, tumor tissue was retrieved. Tissue microarrays (TMA) were performed to analyze the biological modifications associated to ET and mTOR targeting. Triplicate immunohistochemistry of P-AKT/AKT, P-mTOR/mTOR and P-S6 were performed in addition to standard markers. Transcriptomic and RTPCR analyses are also being conducted.
Results. Three models resistant to tamoxifen and 2 models resistant to surgical ovariectomy used a surrogate to estrogen deprivation, were developed from 3 initial PDX, and were maintained as independent hormone-resistant variants. All these models retained a luminal phenotype, based on IHC and transcriptomic analyses and had a wt PI3KCA. ETR models had an expression profile very similar to the initial PDX, suggesting that minor changes may be associated with the acquisition of an ETR phenotype. Three of these models have been tested. One tamoxifen resistant model confirmed a resistance specific to tamoxifen only and a high level of sensitivity to a fulvestrant everolimus combination. A second PDX yielded 2 other models resistant to tamoxifen and ovariectomy. These 2 models developed a resistance to all ET modalities. Therapeutic testing with combinations of everolimus and ETs were highly efficient, but everolimus alone was as efficient in these 2 models with complete and durable responses. Activation of the PI3K pathway was demonstrated in all cases by IHC analyses (expression of pAKT and pS6), and complementary ongoing RTPCR analyses. Everolimus based effects were associated with tumor fibrosis, a strong inhibition of Ki67 and pS6, but not always pAKT. The expression of ER was not modified by treatments, except in the fulvestrant-treated mice where it was strongly inhibited.
Conclusion. We have developed and validated a platform of ETR models derived from our LBC original PDX. These models retained a luminal phenotype although highly resistant to ET. Activation of the PI3K pathway has been confirmed in ETR models, and everolimus alone, or combined with ET confirms high and durable efficacy. Updated mechanistic analyses performed at different time points will be presented at the meeting.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-04-14.
Collapse
Affiliation(s)
- PH Cottu
- Institut Curie, Paris, France; Institut Curie, Saint-Cloud, France; Ecole Veterinaire d'Alfort, Maisons-Alfort, France; Novartis Pharma, Rueil Malmaison, France
| | - T Bagarre
- Institut Curie, Paris, France; Institut Curie, Saint-Cloud, France; Ecole Veterinaire d'Alfort, Maisons-Alfort, France; Novartis Pharma, Rueil Malmaison, France
| | - F Assayag
- Institut Curie, Paris, France; Institut Curie, Saint-Cloud, France; Ecole Veterinaire d'Alfort, Maisons-Alfort, France; Novartis Pharma, Rueil Malmaison, France
| | - I Bièche
- Institut Curie, Paris, France; Institut Curie, Saint-Cloud, France; Ecole Veterinaire d'Alfort, Maisons-Alfort, France; Novartis Pharma, Rueil Malmaison, France
| | - S Chateau-Joubert
- Institut Curie, Paris, France; Institut Curie, Saint-Cloud, France; Ecole Veterinaire d'Alfort, Maisons-Alfort, France; Novartis Pharma, Rueil Malmaison, France
| | - J-J Fontaine
- Institut Curie, Paris, France; Institut Curie, Saint-Cloud, France; Ecole Veterinaire d'Alfort, Maisons-Alfort, France; Novartis Pharma, Rueil Malmaison, France
| | - D Decaudin
- Institut Curie, Paris, France; Institut Curie, Saint-Cloud, France; Ecole Veterinaire d'Alfort, Maisons-Alfort, France; Novartis Pharma, Rueil Malmaison, France
| | - K Slimane
- Institut Curie, Paris, France; Institut Curie, Saint-Cloud, France; Ecole Veterinaire d'Alfort, Maisons-Alfort, France; Novartis Pharma, Rueil Malmaison, France
| | - A Vincent-Salomon
- Institut Curie, Paris, France; Institut Curie, Saint-Cloud, France; Ecole Veterinaire d'Alfort, Maisons-Alfort, France; Novartis Pharma, Rueil Malmaison, France
| | - E Marangoni
- Institut Curie, Paris, France; Institut Curie, Saint-Cloud, France; Ecole Veterinaire d'Alfort, Maisons-Alfort, France; Novartis Pharma, Rueil Malmaison, France
| |
Collapse
|
24
|
Romanelli A, Clark A, Assayag F, Chateau-Joubert S, Poupon MF, Servely JL, Fontaine JJ, Liu X, Spooner E, Goodstal S, de Cremoux P, Bièche I, Decaudin D, Marangoni E. Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts. Mol Cancer Ther 2012; 11:2693-703. [PMID: 23012245 DOI: 10.1158/1535-7163.mct-12-0441-t] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Triple-negative breast cancers (TNBC) have an aggressive phenotype with a relatively high rate of recurrence and poor overall survival. To date, there is no approved targeted therapy for TNBCs. Aurora kinases act as regulators of mammalian cell division. They are important for cell-cycle progression and are frequently overexpressed or mutated in human tumors, including breast cancer. In this study, we investigated the therapeutic potential of targeting Aurora kinases in preclinical models of human breast cancers using a pan-inhibitor of Aurora kinases, AS703569. In vitro, AS703569 was tested in 15 human breast cancer cell lines. TNBC cell lines were more sensitive to AS703569 than were other types of breast cancer cells. Inhibition of proliferation was associated with cell-cycle arrest, aneuploidy, and apoptosis. In vivo, AS703569 administered alone significantly inhibited tumor growth in seven of 11 patient-derived breast cancer xenografts. Treatment with AS703569 was associated with a decrease of phospho-histone H3 expression. Finally, AS703569 combined to doxorubicin-cyclophosphamide significantly inhibited in vivo tumor recurrence, suggesting that Aurora kinase inhibitors could be used both in monotherapy and in combination settings. In conclusion, these data indicate that targeting Aurora kinases could represent a new effective approach for TNBC treatment.
Collapse
|
25
|
Cottu P, Assayag F, Chouchane-Mlik O, Reyal F, De Cremoux P, Gentien D, Chateau-Joubert S, Vincent-Salomon A, Decaudin D, Marangoni E. 81P Response to Endocrine and Targeted Therapies in A Large Panel of Patient-Derived Luminal Breast Cancer Xenografts. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(19)65745-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
26
|
Cottu PH, Assayag F, Chouchane-Mlik O, Reyal F, Cremoux PD, Gentien D, Chateau-Joubert S, Vincent-Salomon A, Poupon MF, Decaudin D, Marangoni E. Abstract LB-352: Reversal of resistance to endocrine therapy by mTOR pathway targeting in a panel of patient derived breast cancer xenografts. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-lb-352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Resistance to endocrine therapy (ET) is a major complication of luminal breast cancers. The aims of this study were: 1) to evaluate the response to endocrine and targeted therapies in a large series of luminal breast cancer xenografts, 2) to generate hormone-resistant xenograft models and 3) to use these models as a support to study ET resistance reversal by mTOR targeting Methods: More than 400 tumor fragments obtained directly from patients with ER+ve breast cancer have been grafted in Swiss nude mice. After stable engraftment, xenografted tumors have been validated by pathology and immunohistochemistry (IHC) examination (ER, PR, HER2 and Ki67). In vivo response to different endocrine treatments (tamoxifen, fulvestrant, ovariectomy and letrozole) was evaluated. ET-resistant variants were generated from tumors growing under continuous therapeutic pressure. Models with intrinsic or acquired resistance to ET were tested with the mTOR inhibitor RAD001, alone and in combination with ET. Molecular analyses will be performed. Results: 12 luminal breast cancer xenografts have been characterized and consistently showed maintenance of the luminal phenotype The genetic profile measured by aCGH for both the patient and xenograft tumors showed a similar profile, stable through the in vivo mice generations. Different patterns of response to ET were observed, thus exhibiting heterogeneity similar to what is observed in the clinic. Five xenograft models with acquired resistance to ET were generated after several months of continuous endocrine therapy and were maintained as independent hormono-resistant variants. Two of them were derived from tumors resistant to tamoxifen and 3 from tumors resistant to ovariectomy, used as a surrogate to estrogen deprivation. IHC analysis showed that expression of ER and PR receptors was conserved in the variant models, while proliferation status assessed by Ki67 expression was generally higher. For all 5 models, resistance to ET was confirmed in further engraftment and ET experiments. RAD001 treatment resulted in a strong anti-tumor effect in the tamoxifen resistant xenograft models and an additive effect was observed when RAD001 was given in combination with tamoxifen or fulvestrant.The PI3K/mTOR pathway status and gene expression profiles will be analyzed in all experiments. Detailed results will be presented at the meeting. Conclusion: We have established a large panel of primary luminal breast cancer xenografts, recapitulating the biological and clinical features of patient tumors. ET resistant variants have been generated, which serve as a preclinical platform to test reversal of resistance to ET, e.g; by mTOR pathway targeting. Molecular studies at the gene and protein expression levels will give an insight of the mechanisms associated with acquired resistance to endocrine treatments.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-352. doi:1538-7445.AM2012-LB-352
Collapse
|
27
|
Petit V, Massonnet G, Maciorowski Z, Touhami J, Fontaine JJ, Thuleau A, Laval J, Chateau-Joubert S, Battini JL, Sitbon M, Decaudin D. Abstract B142: Dissociation of preclinical primary human cancer xenografts for cell surface transportome profiling. Mol Cancer Ther 2011. [DOI: 10.1158/1535-7163.targ-11-b142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor cell metabolism is of growing interest in both basic and clinical cancer research. A better understanding of underlying molecular mechanisms involving metabolite transport in normal and tumor cells should help drug discovery and development. Specific exofacial ligands to metabolite transporters derived from the receptor binding domain (RBD) of retrovirus envelope proteins were developed and used to quantify cell surface metabolite transporters. While cell surface labelling can be readily performed on cultured cell lines, analysis of single cells from solid tumors is more challenging. In this study, we developed a robust method for the disaggregation of tumor cells from human breast cancers grown as xenografts in mice. This procedure was then used to analyse the expression profiles of 4 cell membrane metabolite transporters involved in cell proliferation and tumorigenesis: Glut1, ASCT2, PiT1, and PiT2.
Materials and methods: Eight primary human breast cancer xenografts were used for ex vivo experiments (Marangoni et al 2007). We developed an optimized disaggregation protocol to obtain maximum viable cell recovery from the xenografts. The protocol was validated for presence of CD44+ tumor cells and for cell viability using caspase 3 and DAPI exclusion and subsequently, applied to the xenografts for flow cytometry analyses, immunohistochemistry and ex vivo cell culture. Expression profiles of 4 metabolite transporters were assessed in 5 different human breast cancer xenografts.
Results: The optimal dissociation protocol developed for these tumors combined mild non-enzymatic (non-enzymatic dissociation buffer) and enzymatic (collagenase III/DNase I) steps, followed by cell purification on a dual density Ficoll gradient. Less than 10% of resulting DAPI negative tumor cells were caspase 3 positive. Dissociated cells showed sustained viability in in vitro cultures for at least 12 days. The numbers of CD44+ cells determined by flow cytometry corresponded to those observed by IHC. The expression profiles of Glut1, ASCT2, PiT1, and PiT2 were distinct for each of the five human breast cancers, and metabolite transporter profiles were highly conserved for xenografts derived from the same tumor.
Conclusions: Mouse xenograft implants of human breast cancer tumors were used to optimize and validate a dissociation method for the production of viable single cells. Cell suspensions were then assessed for cell surface metabolite transporters expression by flow cytometry. The expression patterns of four metabolite transporters, Glut1, ASCT2, PiT1, and PiT2 showed distinctive signature profiles for each group of xenografts, indicative of specific metabolic adaptations that can be tracked with our ligands for each tumor.
Reference:
1. Marangoni E et al, CCR 2007;13:3989–3998.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B142.
Collapse
Affiliation(s)
- Vincent Petit
- 1Institut de Genetique Moleculaire de Montpellier, Montpellier, France
| | - Gerald Massonnet
- 2Laboratory of Preclinical Investigation, Inst. Curie, Paris, France
| | | | - Jawida Touhami
- 1Institut de Genetique Moleculaire de Montpellier, Montpellier, France
| | | | - Aurelie Thuleau
- 2Laboratory of Preclinical Investigation, Inst. Curie, Paris, France
| | - Julie Laval
- 1Institut de Genetique Moleculaire de Montpellier, Montpellier, France
| | | | - Jean-Luc Battini
- 1Institut de Genetique Moleculaire de Montpellier, Montpellier, France
| | - Marc Sitbon
- 1Institut de Genetique Moleculaire de Montpellier, Montpellier, France
| | - Didier Decaudin
- 2Laboratory of Preclinical Investigation, Inst. Curie, Paris, France
| |
Collapse
|
28
|
Cassoux N, Assayag F, Chouchane-Mlik O, Fontaine JJ, Nemati F, Thuleau A, N'Doye O, Chateau-Joubert S, Aerts I, Doz F, Piperno-Neumann S, Desjardins L, Decaudin D. Abstract A20: Development and pharmacological assessment of new models of orthotopic primary human uveal melanoma and retinoblastoma xenografts. Mol Cancer Ther 2011. [DOI: 10.1158/1535-7163.targ-11-a20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The treatment of both uveal melanoma and retinoblastoma could require enucleation in unfavorable prognostic disease. In order to allow pharmacological assessment of innovative intraocular treatments in more relevant and predictive models, we have developed preclinical orthotopic xenografts of both primary human uveal melanoma (UM) and retinoblastoma (Rb) into immunodeficient mice.
Materials and methods: Orthotopic models of human UM and Rb have been developed from two panels of subcutaneous xenografts previously established and characterized in the laboratory (Némati et al 2010; Aerts et al 2010), i.e. 6 UM models (MP34, MP41, MP42, MP55, MP65, and MM26) and 3 Rb models (RB102, RB111, and RB200). Mice bearing xenografts were sacrificed and tumors were dissected to obtain a suspension of fresh tumor cells at a concentration of 8000 cells/l in DMEM serum-free medium. Under intraperitoneal anesthesia, 2 l of cell suspension was injected into the subretinal space of the right eye for 3 groups of mice using a 32G needle via a Hamilton syringe. Each group was constituted by 3 to 6 SCID mice. After sub-retinal injection, ophthalmic examination of the mice was performed weekly. When tumor cells invaded vitreal cavity and anterior chamber, the mice were sacrificed for ophthalmological pathological analyzes. Finally, using the RB200 model, we have then evaluated the efficacy of 2 μl intraocular administration of bevacizumab (25 mg/kg/week for 4 weeks), melphalan (500 μg/kg/week for 4 weeks), and carboplatin (100 μg/kg/week for 4 weeks).
Results: The 6 UM cells developed in all injected eyes, 6 to 10 weeks after orthotopic transplantation. Pathological analyzes confirmed UM diagnosis and conservation of histological sub-type, i.e. epithelioid and/or spindle cell, than in corresponding patient's tumors and subcutaneous xenografts. Liver tissues examination is on-going. Rb tumor cells developed in all injected eyes 4 to 6 weeks after orthotopic transplantation for RB102 and RB200. In contrast, no tumor growth was observed in injected eyes of the RB111 model. Pathological examination of the injected eyes confirmed the presence of a massive infiltration of the retina, vitreous and anterior chamber by retinoblastoma cells. Finally, we have observed a high efficacy of intraocular administration of carboplatin (17% of intraocular tumors), but not bevacizumab (100%) nor melphalan (67%), in the RB200 model than in the control group.
Conclusions: We have developed relevant and available preclinical models of human UM and Rb that allow pharmacological assessment of intraocular standard therapies. We will now evaluate innovative therapeutic approaches in such a tumor situation. Némati et al. Clin Cancer Res 2010;16:2352–2362.
Aerts et al. Photodiagnosis Photodyn Ther 2010;7:275–283.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A20.
Collapse
|
29
|
Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader C, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D. Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast Cancer Res Treat 2011; 133:595-606. [PMID: 22002565 DOI: 10.1007/s10549-011-1815-5] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2011] [Accepted: 09/30/2011] [Indexed: 11/28/2022]
Abstract
Resistance to endocrine therapy is a major complication of luminal breast cancer and studies of the biological features of hormonal resistance are limited by the lack of adequate preclinical models. The aim of this study is to establish and characterize a panel of primary human luminal breast carcinoma xenografts, and to evaluate their response to endocrine therapies. Four hundred and twenty-three tumor fragments obtained directly from patients have been grafted in the interscapular fatpad of Swiss nude mice. After stable engraftment with estradiol supplementation, xenografted tumors have been validated by conventional pathology and immunohistochemistry examination, and additional molecular studies. In vivo tumor growth and response to different endocrine treatments were evaluated. We have engrafted 423 tumors including 314 ER+ tumors, and 8 new luminal breast cancer xenografts have been obtained (2.5%). Tumor take was much lower for luminal tumors than for non-luminal tumors (2.5 vs. 24.7%, P < 0.0001), and was associated with two independent criteria, i.e., ER status (P < 0.0001) and a high grade tumor (P = 0.05). Histological and immunohistochemical analyses performed on patient's tumors and xenografts showed striking similarities in the tumor morphology as well as in the expression level of ER, PR, and HER2. Response to hormone therapy, evaluated in 6 luminal models, showed different sensitivities, thus exhibiting heterogeneity similar to what is observed in the clinic. We have established a panel of primary human luminal breast cancer xenografts, recapitulating the biological and clinical behaviors of patient tumors, and therefore suitable for further preclinical experiments.
Collapse
Affiliation(s)
- P Cottu
- Department of Medical Oncology, Institut Curie, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Marangoni E, Clark A, Assayag F, Chateau-Joubert S, Hamini A, Poupon M, Liu E, Spooner A, Romanelli A, Decaudin D. 493 AS703569/R763, a pan Aurora kinase inhibitor, shows strong antitumor activity in vitro and in vivo in a panel of triple-negative breast cancer cell lines and xenografts. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72200-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
31
|
Girard-Luc A, Chateau-Joubert S, Lagadic M, Bernex F. Canine Gastrointestinal Stromal Tumours: Morphological and immunohistochemical study. J Comp Pathol 2009. [DOI: 10.1016/j.jcpa.2009.07.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
32
|
Prioul JL, Méchin V, Lessard P, Thévenot C, Grimmer M, Chateau-Joubert S, Coates S, Hartings H, Kloiber-Maitz M, Murigneux A, Sarda X, Damerval C, Edwards KJ. A joint transcriptomic, proteomic and metabolic analysis of maize endosperm development and starch filling. Plant Biotechnol J 2008; 6:855-69. [PMID: 19548342 DOI: 10.1111/j.1467-7652.2008.00368.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The maize endosperm transcriptome was investigated through cDNA libraries developed at three characteristic stages: (i) lag phase [10 days after pollination (DAP)]; (ii) beginning of storage (14 DAP); and (iii) maximum starch accumulation rate (21 DAP). Expressed sequence tags for 711, 757 and 384 relevant clones, respectively, were obtained and checked manually. The proportion of sequences with no clear function decreased from 35% to 20%, and a large increase in storage protein sequences (i.e. 5% to 38%) was observed from stages (i) to (iii). The remaining major categories included metabolism (11%-13%), transcription-RNA processing-protein synthesis (13%-20%), protein destination (5%-9%), cellular communication (3%-9%) and cell rescue-defence (4%). Good agreement was generally found between category rank in the 10-DAP transcriptome and the recently reported 14-DAP proteome, except that kinases and proteins for RNA processing were not detected in the latter. In the metabolism category, the respiratory pathway transcripts represented the largest proportion (25%-37%), and showed a shift in favour of glycolysis at 21 DAP. At this stage, amino acid metabolism increased to 17%, whereas starch metabolism surprisingly decreased to 7%. A second experiment focused on carbohydrate metabolism by comparing gene expression at three levels (transcripts, proteins and enzyme activities) in relation to substrate or product from 10 to 40 DAP. Here, two distinct patterns were observed: invertases and hexoses were predominant at the beginning, whereas enzyme patterns in the starch pathway, at the three levels, anticipated and paralleled starch accumulation, suggesting that, in most cases, transcriptional control is responsible for the regulation of starch biosynthesis.
Collapse
Affiliation(s)
- Jean Louis Prioul
- Université Paris-Sud, Institut de Biotechnologie des Plantes, Bât. 630, F-91405 Orsay, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Prioul JL, Méchin V, Lessard P, Thévenot C, Grimmer M, Chateau-Joubert S, Coates S, Hartings H, Kloiber-Maitz M, Murigneux A, Sarda X, Damerval C, Edwards KJ. A joint transcriptomic, proteomic and metabolic analysis of maize endosperm development and starch filling. Plant Biotechnol J 2008. [PMID: 19548342 DOI: 10.1111/j1467-7652.2008.00368x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
The maize endosperm transcriptome was investigated through cDNA libraries developed at three characteristic stages: (i) lag phase [10 days after pollination (DAP)]; (ii) beginning of storage (14 DAP); and (iii) maximum starch accumulation rate (21 DAP). Expressed sequence tags for 711, 757 and 384 relevant clones, respectively, were obtained and checked manually. The proportion of sequences with no clear function decreased from 35% to 20%, and a large increase in storage protein sequences (i.e. 5% to 38%) was observed from stages (i) to (iii). The remaining major categories included metabolism (11%-13%), transcription-RNA processing-protein synthesis (13%-20%), protein destination (5%-9%), cellular communication (3%-9%) and cell rescue-defence (4%). Good agreement was generally found between category rank in the 10-DAP transcriptome and the recently reported 14-DAP proteome, except that kinases and proteins for RNA processing were not detected in the latter. In the metabolism category, the respiratory pathway transcripts represented the largest proportion (25%-37%), and showed a shift in favour of glycolysis at 21 DAP. At this stage, amino acid metabolism increased to 17%, whereas starch metabolism surprisingly decreased to 7%. A second experiment focused on carbohydrate metabolism by comparing gene expression at three levels (transcripts, proteins and enzyme activities) in relation to substrate or product from 10 to 40 DAP. Here, two distinct patterns were observed: invertases and hexoses were predominant at the beginning, whereas enzyme patterns in the starch pathway, at the three levels, anticipated and paralleled starch accumulation, suggesting that, in most cases, transcriptional control is responsible for the regulation of starch biosynthesis.
Collapse
Affiliation(s)
- Jean Louis Prioul
- Université Paris-Sud, Institut de Biotechnologie des Plantes, Bât. 630, F-91405 Orsay, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Escoffier N, Gaudin J, Mezhoud K, Huet H, Chateau-Joubert S, Turquet J, Crespeau F, Edery M. Toxicity to medaka fish embryo development of okadaic acid and crude extracts of Prorocentrum dinoflagellates. Toxicon 2007; 49:1182-92. [PMID: 17382985 DOI: 10.1016/j.toxicon.2007.02.008] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2006] [Revised: 02/05/2007] [Accepted: 02/06/2007] [Indexed: 11/27/2022]
Abstract
Chronic and subchronic toxicity following exposure to the DSP (Diarrhetic shellfish poisoning) toxin okadaic acid (OA) is receiving increasing attention as a public human health biohazard. However information on ecological impacts induced by proliferation of the OA producing dinoflagellate Prorocentrum is scarce. In order to analyse the toxicity of these substances, in vivo experiments were conducted on medaka fish (Oryzias latipes) embryos used as an experimental model. The study was focused on two strains of benthic Prorocentrum species, P. arenarium and P. emarginatum, naturally found in the Indian Ocean. Sample extracts (crude extracts, CE) were obtained from algal cultures and their toxic potential was explored. Their OA (and derivatives) content was evaluated by two methods: one based on chemical analysis using HPLC-MS, the other based on screening the inhibiting effect on protein phosphatase PP2A. P. arenarium extracts inhibit PP2A and the active toxin was confirmed as being OA by HPLC-MS. In contrast, P. emarginatum showed negative results regardless of the method used. The development of medaka fish embryos kept in medium containing pure OA or Prorocentrum CE was examined. Survival rates were reduced up to 100% depending on the concentrations used of both OA and CE of P. arenarium, while no effect was observed with CE of P. emarginatum. Anatomopathological studies of surviving embryos indicate that OA treatment resulted in significant increases in liver and digestive tract areas compared to controls. P. arenarium treated surviving embryos exhibited significant quantitative increases of global body and vitellus areas. Together, our results indicate that the toxic effects to medaka embryos development of pure OA and P. arenarium extracts containing OA are distinguishable. The differences may indicate the presence of additional toxic substance(s) (or molecules able to modulate OA impact) in the P. arenarium CE that probably are not present in P. emarginatum.
Collapse
Affiliation(s)
- Nicolas Escoffier
- USM 0505 Ecosystèmes et Interactions Toxiques, Muséum National d'Histoire Naturelle, RDDM, 12 rue Buffon, F-75231, Paris Cedex 05, France
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Trouverie J, Chateau-Joubert S, Thévenot C, Jacquemot MP, Prioul JL. Regulation of vacuolar invertase by abscisic acid or glucose in leaves and roots from maize plantlets. Planta 2004; 219:894-905. [PMID: 15179513 DOI: 10.1007/s00425-004-1289-3] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/13/2004] [Accepted: 04/13/2004] [Indexed: 05/24/2023]
Abstract
Recent studies have demonstrated in leaves of maize (Zea mays L.) plants submitted to a moderate water stress an early enhancement of vacuolar invertase activity that paralleled the expression of the vacuolar invertase Ivr2 gene and the accumulation of hexoses. In this paper, the direct role of abscisic acid (ABA) was checked by providing this hormone to the root medium of hydroponically grown maize plantlets. ABA supplied to 10-day-old seedlings appeared to enhance the vacuolar invertase activity within 1 h in roots and 2 h in leaves, the maximum being reached at 4 and 8 h, respectively. The Ivr2 gene expression varied accordingly, except that the maximum values were earlier. During the first 8 h of activity enhancement, hexose and sucrose concentrations were not significantly affected by ABA. The changes in activity were correlated to leaf and root ABA concentrations and they were concentration dependent in roots and leaves. In contrast, the addition of 1% glucose or polyethylene glycol, at the same osmotic potential, was ineffective on invertase activity, but glucose supply enhanced Ivr2 transcript levels, after 18 h, in a concentration-dependent manner in the leaf, whereas they were repressed at higher concentrations in intact roots. The latter result appeared specific to intact roots since similar treatments performed using excised leaf or root pieces confirmed a previous report on the enhancement of Ivr2 and Ivr1 transcript levels by glucose in roots [J. Xu et al. (1996) Plant Cell 8:1209-1220]. Therefore, ABA appears to be a strong inducer of Ivr2-invertase expression in roots and leaves.
Collapse
Affiliation(s)
- Jacques Trouverie
- Laboratoire Structure et Métabolisme des Plantes, Institut de Biotechnologie des Plantes (UMR-CNRS 8618), Bâtiment 630, Université Paris-Sud, 91405, Orsay Cedex, France
| | | | | | | | | |
Collapse
|